Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2025; 16(11): 111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6
Gang Wang, Yi-Rong Li, Jing-Lan Wang, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China
Gang Wang, Tao Liu, Jia-Xing Zhang, Yi-Rong Li, Wei-Jing Zhu, Jing-Lan Wang, Wei-Wei Dong, Yu-Yu Zhang, Yu-Min Li, Lu-Xi Yang, Wen-Ting He, Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou University, Lanzhou 730000, Gansu Province, China
Tao Liu, Jia-Xing Zhang, Wei-Jing Zhu, Wei-Wei Dong, Yu-Yu Zhang, Yu-Min Li, Lu-Xi Yang, Wen-Ting He, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, Gansu Province, China
Li-Xia He, Division of Molecular and Cellular Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, United States
Co-corresponding authors: Li-Xia He and Wen-Ting He.
Author contributions: Wang G and Liu T planned and conducted the whole research and wrote the first draft of the manuscript; Zhang JX and Li YR contributed to the conception of the manuscript; Wang JL, Dong WW, Zhang YY, and Zhu WJ contributed to analyzing the data and revising the manuscript; Li YM and Yang LX overall supervised this study; He LX and He WT reviewed the literature and designed the outline of the paper. He WT and He LX contributed equally to this work as co-corresponding authors. All the authors have read and agreed to the published version of the manuscript.
Supported by the Science and Technology Program of Gansu Province, No. 23JRRA1015; the International Science and Technology Cooperation Project of Gansu Provincial Science and Technology Department, No. 2023YFWA0009; and the Innovation and Entrepreneurship Project for Young Talents of Lanzhou Science and Technology Bureau, No. 2023-4-18.
Institutional review board statement: The study protocol was met with the declaration of Helsinki and was approved by the Ethics Committee of Shanghai Outdo Biotech Company (Approval No. SHYJS-CP-1904003).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: If relevant data are needed, please contact the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Ting He, PhD, The Second Hospital & Clinical Medical School, Lanzhou University, No. 82 Cuiyingmen, Chengguan District, Lanzhou 730030, Gansu Province, China. hewt@lzu.edu.cn
Received: July 7, 2025
Revised: July 23, 2025
Accepted: October 10, 2025
Published online: November 24, 2025
Processing time: 139 Days and 22.2 Hours
Revised: July 23, 2025
Accepted: October 10, 2025
Published online: November 24, 2025
Processing time: 139 Days and 22.2 Hours
Core Tip
Core Tip: Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6), a member of the ENTPD family, was highly expressed in kidney renal clear cell carcinoma, liver hepatocellular carcinoma, kidney renal papillary cell carcinoma, endocervical adenocarcinoma, and other malignancies, indicating it could be a potential biomarker. In this study, we performed a comprehensive analysis examining the correlation between ENTPD6 expression and various factors, including prognosis, genetic alterations, epigenetic modification, immune infiltration, immunotherapy responses, functional enrichment, and drug sensitivity. Our findings yield novel insights into the role of ENTPD6 in cancer biology and bolster global research on its potential as a therapeutic target.